Hereditary Hemorrhagic Telangiectasia clinical trials at UCSD
1 research study open to eligible people
open to eligible people ages 18 years and up
This is a Phase II placebo-controlled double-blind study of pomalidomide in patients with hereditary hemorrhagic telangiectasia (HHT) with moderate to severe epistaxis who have anemia and/or require parenteral iron infusions or blood transfusions. A total of 159 patients will be randomized 2:1 to treatment with oral pomalidomide or matching placebo for 24 weeks. Mean change from baseline to 24 weeks in the Epistaxis Severity Score (ESS) will be compared between treatment groups to determine pomalidomide efficacy.
San Diego, California and other locations
Our lead scientists for Hereditary Hemorrhagic Telangiectasia research studies include Jenny Zhou, MD.